123 related articles for article (PubMed ID: 38225773)
1. MRI-defined T3, clear mesorectal fascia mid-low rectal cancer: is neoadjuvant treatment necessary?
Zeng Z; Li Z; Luo S; Huang L; Liang Z; Zheng X; Li W; Xiong L; Liu H; Kang L
J Gastroenterol Hepatol; 2024 May; 39(5):858-867. PubMed ID: 38225773
[TBL] [Abstract][Full Text] [Related]
2. MRI-defined high-risk rectal cancer patients: outcome comparison between neoadjuvant chemoradiotherapy plus TME and TME plus adjuvant chemotherapy or TME alone.
Jia X; Xie P; Bi L; Meng X; Wang Z; Hong N; Wang Y
Br J Radiol; 2021 Apr; 94(1120):20201221. PubMed ID: 33591799
[TBL] [Abstract][Full Text] [Related]
3. Avoidance of Overtreatment of Rectal Cancer by Selective Chemoradiotherapy: Results of the Optimized Surgery and MRI-Based Multimodal Therapy Trial.
Ruppert R; Kube R; Strassburg J; Lewin A; Baral J; Maurer CA; Sauer J; Junginger T; Hermanek P; Merkel S;
J Am Coll Surg; 2020 Oct; 231(4):413-425.e2. PubMed ID: 32697965
[TBL] [Abstract][Full Text] [Related]
4. Oncological outcome after MRI-based selection for neoadjuvant chemoradiotherapy in the OCUM Rectal Cancer Trial.
Ruppert R; Junginger T; Ptok H; Strassburg J; Maurer CA; Brosi P; Sauer J; Baral J; Kreis M; Wollschlaeger D; Hermanek P; Merkel S;
Br J Surg; 2018 Oct; 105(11):1519-1529. PubMed ID: 29744860
[TBL] [Abstract][Full Text] [Related]
5. Selective lateral lymph node dissection after neoadjuvant chemoradiotherapy in rectal cancer.
Chen JN; Liu Z; Wang ZJ; Mei SW; Shen HY; Li J; Pei W; Wang Z; Wang XS; Yu J; Liu Q
World J Gastroenterol; 2020 Jun; 26(21):2877-2888. PubMed ID: 32550762
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcomes of surgery alone versus surgery following preoperative chemoradiotherapy for early T3 rectal cancer: A propensity score analysis.
Cho SH; Choi GS; Kim GC; Seo AN; Kim HJ; Kim WH; Shin KM; Lee SM; Ryeom H; Kim SH
Medicine (Baltimore); 2017 Mar; 96(12):e6362. PubMed ID: 28328820
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of the EMD/mesorectum ratio of T3 mid-low rectal cancer: A retrospective observational study.
Gu C; Yang X; Zhang X; Zheng E; Deng X; Hu T; Wu Q; Bi L; Wu B; Su M; Wang Z
Medicine (Baltimore); 2018 Nov; 97(48):e13468. PubMed ID: 30508974
[TBL] [Abstract][Full Text] [Related]
8. Total Mesorectal Excision Versus Local Excision After Favorable Response to Preoperative Chemoradiotherapy in "Early" Clinical T3 Rectal Cancer: A Propensity Score Analysis.
Shin YS; Yu CS; Park JH; Kim JC; Lim SB; Park IJ; Kim TW; Hong YS; Kim KP; Yoon SM; Joo JH; Kim JH
Int J Radiat Oncol Biol Phys; 2017 Sep; 99(1):136-144. PubMed ID: 28816139
[TBL] [Abstract][Full Text] [Related]
9. [Rectum-preserving surgery after consolidation neoadjuvant therapy or totally neoadjuvant therapy for low rectal cancer: a preliminary report].
Huang Y; Huang SH; Chi P; Wang XJ; Lin HM; Lu XR; Ye DX; Lin Y; Deng Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):281-288. PubMed ID: 32192308
[No Abstract] [Full Text] [Related]
10. Changing operative strategy from abdominoperineal resection to sphincter preservation in T3 low rectal cancer after downstaging by neoadjuvant chemoradiation: a preliminary report.
Madbouly KM; Hussein AM
World J Surg; 2015 May; 39(5):1248-56. PubMed ID: 25561197
[TBL] [Abstract][Full Text] [Related]
11. [Comparison of long-term efficacy between watch and wait strategy and total mesorectal excision in locally advanced rectal cancer patients with clinical complete response after neoadjuvant therapy].
Wang XH; Zhou CJ; Zhang S; Wang QX; Xiao WW; Ding PR; Chen G; Pan ZZ; Zeng ZF; Gao YH
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):266-273. PubMed ID: 32192306
[No Abstract] [Full Text] [Related]
12. The influence of neoadjuvant chemoradiotherapy combined with lateral lymph nodes dissection or not on the local recurrence of low to intermediate-stage II/III rectal cancer.
Li C; Luan J; Ji X; Wang X; Li J; Li X; Zhou Y
J Surg Oncol; 2024 Feb; 129(2):273-283. PubMed ID: 37811551
[TBL] [Abstract][Full Text] [Related]
13. Influence of neoadjuvant treatment strategy on perioperative outcomes in locally advanced rectal cancer.
McFeetors C; O'Connell LV; Choy M; Dundon N; Regan M; Joyce M; Meshkat B; Hogan A; Nugent E
Colorectal Dis; 2024 Apr; 26(4):684-691. PubMed ID: 38424706
[TBL] [Abstract][Full Text] [Related]
14. Is neoadjuvant chemoradiotherapy always necessary for mid/high local advanced rectal cancer: A comparative analysis after propensity score matching.
Zhang Y; Sun Y; Xu Z; Chi P; Lu X
Eur J Surg Oncol; 2017 Aug; 43(8):1440-1446. PubMed ID: 28502421
[TBL] [Abstract][Full Text] [Related]
15. Robotic versus laparoscopic sphincter-saving total mesorectal excision for mid or low rectal cancer in male patients after neoadjuvant chemoradiation therapy: comparison of long-term outcomes.
Asoglu O; Tokmak H; Bakir B; Aliyev V; Saglam S; Iscan Y; Bademler S; Meric S
J Robot Surg; 2020 Jun; 14(3):393-399. PubMed ID: 31313071
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of neoadjuvant chemoradiotherapy followed by total mesorectal excision surgery for locally advanced rectal cancer: a single-institution experience.
Tseng MSF; Zheng H; Ng IWS; Leong YH; Leong CN; Yong WP; Cheong WK; Tey JCS
Singapore Med J; 2018 Jun; 59(6):305-310. PubMed ID: 29167909
[TBL] [Abstract][Full Text] [Related]
17. [Safety and prognosis analysis of transanal total mesorectal excision versus laparoscopic mesorectal excision for mid-low rectal cancer].
Sun R; Cong L; Qiu HZ; Lin GL; Wu B; Niu BZ; Sun XY; Zhou JL; Xu L; Lu JY; Xiao Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2022 Jun; 25(6):522-530. PubMed ID: 35754217
[No Abstract] [Full Text] [Related]
18. Is it time to rethink the rule of total mesorectal excision? A prospective radiological and pathological study in 49 consecutive patients with mid-rectal cancer.
Guedj N; Zappa M; Maggiori L; Bertin C; Hennequin C; Panis Y
Colorectal Dis; 2016 Sep; 18(9):O314-21. PubMed ID: 27381492
[TBL] [Abstract][Full Text] [Related]
19. Korean Society of Coloproctology (KSCP) trial of cONsolidation Chemotherapy for Locally advanced mid or low rectal cancer after neoadjUvant concurrent chemoraDiothErapy: a multicenter, randomized controlled trial (KONCLUDE).
Kim CW; Kang BM; Kim IY; Kim JY; Park SJ; Park WC; Bae KB; Bae BN; Baek SK; Baik SH; Son GM; Lee YS; Lee SH
BMC Cancer; 2018 May; 18(1):538. PubMed ID: 29739356
[TBL] [Abstract][Full Text] [Related]
20. Indistinguishable T2/T3-N0 rectal cancer on rectal magnetic resonance imaging: comparison of surgery-first and neoadjuvant chemoradiation therapy-first strategies.
Kim JG; Song KD; Cha DI; Kim HC; Yu JI
Int J Colorectal Dis; 2018 Oct; 33(10):1359-1366. PubMed ID: 30003363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
